dc.contributor.author | Carbonell-Estrany, Xavier | |
dc.contributor.author | González Pérez-Yarza, Eduardo | |
dc.contributor.author | Sanchez García, Laura | |
dc.contributor.author | Guzmán Cabañas, Juana M. | |
dc.contributor.author | Villarrubia Bòria, Elena | |
dc.contributor.author | Bernardo Atienza, Belén | |
dc.contributor.author | IRIS (Infección Respiratoria Infantil por Virus Respiratorio Sincitial) Study Group | |
dc.date.accessioned | 2016-05-10T13:12:35Z | |
dc.date.available | 2016-05-10T13:12:35Z | |
dc.date.issued | 2015-05-08 | |
dc.identifier.citation | Plos One 10(5) : (2015) // Article ID e0125422 | es |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | http://hdl.handle.net/10810/18211 | |
dc.description.abstract | The health status of premature infants born 32(1)-35(0) weeks' gestational age (wGA) hospitalized for RSV infection in the first year of life (cases; n = 125) was compared to that of premature infants not hospitalized for RSV (controls; n = 362) through 6 years. The primary endpoints were the percentage of children with wheezing between 2-6 years and lung function at 6 years of age. Secondary endpoints included quality of life, healthcare resource use, and allergic sensitization. A significantly higher proportion of cases than controls experienced recurrent wheezing through 6 years of age (46.7% vs. 27.4%; p = 0.001). The vast majority of lung function tests appeared normal at 6 years of age in both cohorts. In children with pulmonary function in the lower limit of normality (FEV1 Z-score [-2; -1]), wheezing was increased, particularly for cases vs. controls (72.7% vs. 18.9%, p = 0.002). Multivariate analysis revealed the most important factor for wheezing was RSV hospitalization. Quality of life on the respiratory subscale of the TAPQOL was significantly lower (p = 0.001) and healthcare resource utilization was significantly higher (p<0.001) in cases than controls. This study confirms RSV disease is associated with wheezing in 32-35 wGA infants through 6 years of age. | es |
dc.description.sponsorship | This study was funded by AbbVie Farmaceutica S.L.U. Madrid, Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | es |
dc.language.iso | eng | es |
dc.publisher | Public Library Science | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.subject | quality-of- life | es |
dc.subject | infection requiring hospitalization | es |
dc.subject | 1st 6 years | es |
dc.subject | lung-function | es |
dc.subject | risk-factors | es |
dc.subject | premature infants | es |
dc.subject | RSV bronchiolitis | es |
dc.subject | gestational-age | es |
dc.subject | palivizumab prophylaxis | es |
dc.subject | spanish version | es |
dc.title | Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants — The SPRING Study | es |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.holder | © 2015 Carbonell-Estrany et al. This is
an open access article distributed under the terms of
the
Creative Commons Attribution License
, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited | es |
dc.relation.publisherversion | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0125422#abstract0 | es |
dc.identifier.doi | 10.1371/journal.pone.0125422 | |
dc.departamentoes | Pediatría | es_ES |
dc.departamentoeu | Pediatria | es_ES |
dc.subject.categoria | AGRICULTURAL AND BIOLOGICAL SCIENCES | |
dc.subject.categoria | BIOCHEMISTRY AND MOLECULAR BIOLOGY | |
dc.subject.categoria | MEDICINE | |